YL202
As of the edition of 20 October 2026, YL202 is a drug known only by a code name: in active development; acts on ERBB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 4, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Digestive system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ERBB3 | Receptor tyrosine-protein kinase erbB-3 | P21860 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| MediLink Therapeutics | Lead sponsor of trials | 2022 to now |